Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Pharmacogenomics of antidiabetic agents: current evidence and implications for precision medicine.

Created on 13 Nov 2026

Authors

Shravan Venkatraman, Hemasri Velmurugan, Sandhiya Selvarajan

Published in

Drug metabolism and personalized therapy. Nov 13, 2026. Epub Nov 13, 2026.

Abstract

Diabetes mellitus, a noncommunicable disease, is controlled with antidiabetic medications. However, interindividual variations require tailored therapy with suitable drugs to achieve glycemic control. Very few studies have focused on candidate genes that regulate drug transport and the target sensitivity of antidiabetic drugs. These genes help predict treatment efficacy, adverse reactions, and long-term maintenance of glycemic control, particularly by reducing the risk of severe hypoglycemia and therapeutic failure. Pharmacogenomics has paved the way for personalized therapy and the identification of novel targets. This review will cover the genes involved in type 2 diabetes mellitus, mainly SLC2A2, SLC47A1, SLC47A2, CYP2C9, SUR1, GLP1R, TCF7L2, ABCC8, and KCNQ1, associated with various antidiabetic drugs.

PMID:
43021722
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement